Tolterodine does not affect memory assessed by passive-avoidance response test in mice

European Journal of Pharmacology

Volumn 579, Issue 1-3, 2008, Pages 225-228

  Cappon, Gregg D ^a   Bush, Brian ^a   Newgreen, Donald ^b   Finch, Gregory L ^a   Alper, Richard H ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

(Mouse); Memory; Passive avoidance; Tolterodine

Indexed keywords

DRUG METABOLITE; SCOPOLAMINE; TOLTERODINE;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; MALE; MEMORY; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL;

ANIMALS; AVOIDANCE LEARNING; BENZHYDRYL COMPOUNDS; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MEMORY; MICE; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; RANDOM ALLOCATION; SCOPOLAMINE; SPECIES SPECIFICITY;

EID: 37549018986     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.063     Document Type: Article

References (19)

1. Andersson K.E., and Yoshida M. Antimuscarinics and the overactive detrusor-which is the main mechanism of action?. Eur. Urol. 43 (2003) 1-5
2. Andersson S.H.G., Lindgren A., and Postlind H. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats and dogs. Drug Metab. Dispos. 26 (1998) 528-535
3. Byrnne N., Stahl M.M.S., Hallen B., Edlund P.O., Palmer L., Hoglund P., and Gabrielsson J. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int. J. Clin. Pharmacol. Ther. 35 (1997) 287-295
4. 3-receptors mediate contraction of human detrusor muscle in vitro. J. Auton. Pharm. 21 (2001) 243-248
5. Diefenbach K., Donath F., Maurer A., Bravo S.Q., Wernecke K., Schwantes U., Haselmann J., and Roots I. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin. Drug Investig. 23 (2003) 395-404
6. Diefenbach K., Arnold G., Wollny A., Schwates U., Haselmann J., and Roots I. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥ 50 years. BJU 95 (2005) 346-349
7. Flaherty C.F. Animal Learning and Cognition (1985), Random House, New York
8. Garely A.D., and Burrows L. Benefit-risk assessment of tolterodine in treatment of overactive bladder in adults. Drug Safety 27 (2004) 1043-1057
9. Gyermek L. Pharmacology of Antimuscarinic Agents (1998), CRC Press, Boca Raton, FL
10. Kay M.A., Messer W., Murphy D., Tsao J., Phil D., and Ouslander J. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J. Am. Geriatr. Soc. 53 (2005) 2195-2201
11. Katz I.R., Sands L.P., Bilker W., DiFilippo S., Boyce A., and D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J. Am. Geriatr. Soc. 46 (1998) 8-13
12. Nilvebrant L. The mechanism of action of tolterodine. Rev. Contemp. Pharmacother. 11 (2000) 13-27
13. Nilvebrant L., Gillberg P., and Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol. Toxicol. 81 (1997) 169-172
14. Oki T., Kageyama A., Takagi Y., Uchida S., and Yamada S. Comparative evaluation of central muscarinic receptor activity of oxybutynin, tolterodine, and darifenacin used to treat overactive bladder. J. Urol. 177 (2007) 766-770
15. Power A.E., Vazdarjanova A., and McGaugh J.L. Muscarinic cholinergic influences in memory consolidation. Neurobiol. Learn. Mem. 80 (2003) 178-193
16. Suzuki M., Noguchi Y., Okutsu H., Ohtake A., and Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur. J. Pharm. 557 (2007) 154-158
17. Todorova A., Vonderheid-Guth B., and Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol. 41 (2001) 636-644
18. Volpicelli L.A., and Levey A.I. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog. Brain Res. 145 (2004) 59-66
19. Yarker Y.E., Goa K.L., and Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6 (1995) 243-262